Coronavirus | Bharat Biotech ropes in 13,000 volunteers for Covaxin phase-III trials

Covaxin is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).

Updated - December 22, 2020 10:21 pm IST

Published - December 22, 2020 12:46 pm IST - Hyderabad

File photo of a medic administering Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, during the phase- III trial.

File photo of a medic administering Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, during the phase- III trial.

Vaccine maker Bharat Biotech has recruited 13,000 of the 26,000 volunteers for the ongoing phase-III clinical trials of its COVID-19 vaccine candidate Covaxin.

“We sincerely thank all the 13,000 volunteers across the country for their support in enabling us to bring out a safe and efficacious Indian vaccine for COVID-19. This pro-vaccine public health volunteerism is a morale boost for us to achieve our milestone target of 26,000 soon – Thank you volunteers,” said Suchitra Ella, Joint MD, Bharat Biotech.

Covaxin is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).

A release from the company said the phase-III human clinical trials began in mid-November and targeted 26,000 volunteers across the country. It is India’s first and only phase-III efficacy study for a COVID-19 vaccine, and the largest phase-III efficacy trial ever conducted for any vaccine in the country.

Covaxin has been evaluated in approximately 1,000 subjects in phase I and phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer reviewed scientific journals, Bharat Biotech said.

The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level-3) bio-containment facility in Genome Valley, Hyderabad.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.